Your search has found 97 articles in the database for the term 'Capacity to carry out day-to-day tasks'
Click
here to filter this large number of results.
The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial
Joling, Karlijn J,
Bosmans, Judith E,
van Marwijk, Harm WJ,
van der Horst, Henriëtte E,
Scheltens, Philip,
Vroomen, Janet L,
van Hout, Hein PJ
...per dyad €4,149, 95% CI -13,371 to 21,956, ICER 157,534). The main cost driver was informal care (66% of total costs), followed by patients’ day treatment and costs of hospital...
Adverse drug reactions in elderly subjects hospitalized in a specialized dementia management unit
Kanagaratnam, Lukshe,
Mahmoudi, Rachid,
Novella, Jean-Luc,
Jolly, Damien,
Dramé, Moustapha,
Trenque, Thierry
...of ADRs was 24 %. Patients were taking 8 ± 3 drugs per day; 72 (24.6 %) were taking more than three psychotropics. The main therapeutic classes prescribed were anxiolytics...
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial
Banerjee, Sube,
Hellier, Jennifer,
Dewey, Michael,
Romeo, Renee,
Ballard, Clive,
Baldwin, Robert,
Bentham, Peter,
Fox, Chris,
Holmes, Clive,
Katona, Cornelius,
Knapp, Martin,
Lawton, Claire,
Lindesay, James,
Livingston, Gill,
McCrae, Niall,
Moniz-Cook, Esme,
Murray, Joanna,
Nurock, Shirley,
Orrell, Martin,
O'Brien, John,
Poppe, Michaela,
Thomas, Alan,
Walwyn, Rebecca,
Wilson, Kenneth,
Burns, Alistair
...sizes, in a 1:1:1 ratio to receive sertraline (target dose 150 mg per day), mirtazapine (45 mg), or placebo (control group), all with standard care. The primary outcome was reduction...
Silicon-rich mineral water as a non-invasive test of the ‘aluminum hypothesis’ in Alzheimer’s disease
Davenward, Samantha,
Bentham, Peter,
Wright, Jan,
Crome, Peter,
Job, Deborah,
Polwart, Anthony,
Exley, Christopher
...1 L of a silicon-rich mineral water each day for 12 weeks facilitated the removal of aluminum via the urine in both patient and control groups without any concomitant affect...
Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study
del Ser, Teodoro,
Steinwachs, Klaus C.,
Gertz, Hermann J.,
Andrés, María V.,
Gómez-Carrillo, Belén,
Medina, Miguel,
Vericat, Joan A.,
Redondo, Pilar,
Fleet, David,
Leon, Teresa
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer’s disease (AD) patients. Thirty mild-moderate...
Effect of a computerized brain exercise program on cognitive performance in older adults
Miller, Karen J.,
Dye, Richelin V.,
Kim, Jeanne,
Jennings, Julia L.,
O'Toole, Elizabeth,
Wong, Julie,
Siddarth, Prabha
...program 5 days a week for 20-25 minutes each day, or a wait-list control group (N = 33). All were older adults without dementia (mean age: 81.8 years; SD: 6.1;...
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease
Grove, Richard A.,
Harrington, Conn M.,
Mahler, Andreas,
Beresford, Isabel,
Maruff, Paul,
Lowy, Martin T.,
Nicholls, Andrew P.,
Boardley, Rebecca L.,
Berges, Alienor C.,
Nathan, Pradeep J.,
Horrigan, Joseph P.
...20µg doses. There were no clinically relevant changes in other safety parameters.; Conclusion: GSK239512, at doses up to 80µg/day, improved Episodic Memory in patients with mildto- moderate AD. However, no...